Last reviewed · How we verify

ARM A : IV iron + epoietin zeta

Centre Francois Baclesse · FDA-approved active Small molecule

ARM A : IV iron + epoietin zeta is a Iron supplement + Erythropoiesis-stimulating agent (ESA) Small molecule drug developed by Centre Francois Baclesse. It is currently FDA-approved for Chemotherapy-induced anemia in cancer patients.

This combination therapy replenishes iron stores and stimulates red blood cell production to treat chemotherapy-induced anemia.

This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia. Used for Chemotherapy-induced anemia, Anemia in cancer patients.

At a glance

Generic nameARM A : IV iron + epoietin zeta
SponsorCentre Francois Baclesse
Drug classIron supplement + Erythropoiesis-stimulating agent (ESA)
TargetErythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
ModalitySmall molecule
Therapeutic areaHematology/Oncology
PhaseFDA-approved

Mechanism of action

IV iron provides the essential substrate for hemoglobin synthesis, while epoetin zeta (a recombinant erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells. Together, they address both iron deficiency and inadequate erythropoietin signaling in anemic patients, particularly those undergoing cancer treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ARM A : IV iron + epoietin zeta

What is ARM A : IV iron + epoietin zeta?

ARM A : IV iron + epoietin zeta is a Iron supplement + Erythropoiesis-stimulating agent (ESA) drug developed by Centre Francois Baclesse, indicated for Chemotherapy-induced anemia in cancer patients.

How does ARM A : IV iron + epoietin zeta work?

This combination therapy replenishes iron stores and stimulates red blood cell production to treat chemotherapy-induced anemia.

What is ARM A : IV iron + epoietin zeta used for?

ARM A : IV iron + epoietin zeta is indicated for Chemotherapy-induced anemia in cancer patients.

Who makes ARM A : IV iron + epoietin zeta?

ARM A : IV iron + epoietin zeta is developed and marketed by Centre Francois Baclesse (see full Centre Francois Baclesse pipeline at /company/centre-francois-baclesse).

What drug class is ARM A : IV iron + epoietin zeta in?

ARM A : IV iron + epoietin zeta belongs to the Iron supplement + Erythropoiesis-stimulating agent (ESA) class. See all Iron supplement + Erythropoiesis-stimulating agent (ESA) drugs at /class/iron-supplement-erythropoiesis-stimulating-agent-esa.

What development phase is ARM A : IV iron + epoietin zeta in?

ARM A : IV iron + epoietin zeta is FDA-approved (marketed).

What are the side effects of ARM A : IV iron + epoietin zeta?

Common side effects of ARM A : IV iron + epoietin zeta include Hypertension, Thromboembolism, Iron overload / hemochromatosis, Injection site reactions, Headache.

What does ARM A : IV iron + epoietin zeta target?

ARM A : IV iron + epoietin zeta targets Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis and is a Iron supplement + Erythropoiesis-stimulating agent (ESA).

Related